Macquarie Group Limited 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-07 07:44 am Sale | 2024-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Macquarie Group Limited | 4,259,557 4.900% | -486,587 (-10.25%) | Filing |
| 2024-02-14 06:38 am Purchase | 2023-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Macquarie Group Limited | 4,746,144 6.310% | 1,190,152 (+33.47%) | Filing |
| 2023-02-14 3:22 pm Sale | 2022-12-30 | 13G | Travere Therapeutics, Inc. TVTX | Macquarie Group Limited | 3,555,992 5.540% | -211,900 (-5.62%) | Filing |
| 2022-02-14 10:24 am Purchase | 2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Macquarie Group Limited | 3,767,892 6.150% | 1,003,970 (+36.32%) | Filing |
| 2021-02-12 08:41 am Purchase | 2020-12-31 | 13G | Travere Therapeutics, Inc. TVTX | Macquarie Group Limited | 2,763,922 5.410% | 2,763,922 (New Position) | Filing |